Dovitinib (dilactic acid)

Dovitinib (dilactic acid)

• CAS Number: 852433-84-2
• UNSPSC Description: Dovitinib (dilactic acid) is an orally active inhibitor of VEGF kinase. Dovitinib (dilactic acid) inhibits receptor tyrosine kinases (RTKs) involved in solid and hematologic cancers and tumor angiogenesis[1].
• Target Antigen: VEGFR
• Type: Reference compound
• Related Pathways: Protein Tyrosine Kinase/RTK
• Applications: Cancer-Kinase/protease
• Field of Research: Cancer
• Assay Protocol: https://www.medchemexpress.com/dovitinib-dilactic-acid.html
• Solubility: DMSO : ≥ 30 mg/mL
• Smiles: CC(O)C(O)=O.CC(O)C(O)=O.O=C1NC2=C(C(F)=CC=C2)C(N)=C1C3=NC4=CC=C(N5CCN(C)CC5)C=C4N3
• Molecular Weight: 572.59
• References & Citations: [1]Zhu, S., et al. The Chemical Development of CHIR-258. CHIMIA International Journal for Chemistry, 60(9), 584–592.
• Shipping Conditions: Room temperature
• Clinical Information: Phase 3